biogen/eisai halt develop aducanumab
alzheim share fall
event march eisai announc discontinu two
global phase trial engag emerg design evalu
efficaci safeti aducanumab patient mild cognit impair
due alzheim diseas mild alzheim diseas dementia
share price fell day close decis
came wake futil analysi independ data monitor
committe conclud trial unlik meet primari
endpoint move driven safeti issu biogen/eisai plan
present detail analys result futur medic confer
invest overview announc serv underscor yet
difficult develop drug treat alzheim diseas base
pharmavalu analysi aducanumab valu account eisai
share price npv expect eisai share trade around
mark near term note chang
develop strategi elenbecestat
joint develop eisai alzheim diseas
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
issuanc retir stock
net chang cash
number share mn
compani mention price
